Selank: The Immune-Derived Peptide with Anxiolytic Properties
Selank is a synthetic heptapeptide created by fusing the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) with a stabilizing Pro-Gly-Pro sequence at the C-terminus. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences alongside its sister compound Semax, Selank was designed to combine immune-modulating properties with neurotropic effects (Zozulya et al., 2001).
Selank has been approved in Russia as an anxiolytic and nootropic medication, distinguished from benzodiazepines by its lack of sedation, addiction potential, and cognitive impairment — properties that have drawn considerable international research interest.
Molecular Profile
- Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (Tuftsin + PGP extension)
- Amino acids: 7 (heptapeptide)
- Molecular weight: ~751.9 Da
- CAS number: 129954-34-3
- Parent molecule: Tuftsin (endogenous immunostimulatory tetrapeptide)
- Modification: C-terminal Pro-Gly-Pro stabilization sequence
- Administration route studied: Intranasal (primary), subcutaneous
Mechanism of Action
Selank's dual anxiolytic-immunomodulatory profile stems from its chimeric design. The tuftsin component activates immune pathways, while the complete molecule demonstrates independent neurotropic activity (Kozlovskii and Danchev, 2003):
- GABAergic modulation: Selank influences GABA receptor-mediated neurotransmission, enhancing inhibitory signaling without direct benzodiazepine receptor binding
- Enkephalin stabilization: Inhibition of enkephalin-degrading enzymes increases endogenous opioid peptide availability, contributing to anxiolytic and mood-modulating effects
- Monoamine regulation: Modulation of serotonin metabolism and dopamine turnover in key brain regions
- Neurotrophic factor expression: Upregulation of BDNF and NGF, similar to but distinct from its sister compound Semax
- Immune activation: Enhancement of phagocytic activity and cytokine regulation through retained tuftsin bioactivity
Research Area 1: Anxiolytic Effects
The anxiolytic properties of Selank have been extensively documented. Seredenin et al. (1998) demonstrated that Selank produced significant anxiolytic effects in the elevated plus maze, light-dark box, and conflict behavior models in rodents. Crucially, the anxiolytic activity was comparable to diazepam in potency but lacked the sedative, muscle-relaxant, and amnestic side effects characteristic of benzodiazepines.
Narkevich et al. (2008) showed that Selank's anxiolytic effects were accompanied by altered monoamine metabolism in the hypothalamus and hippocampus, with increased serotonin and its metabolite 5-HIAA in brain regions associated with anxiety regulation.
Zozulya et al. (2001) conducted clinical investigations confirming that Selank demonstrated anxiolytic efficacy in human subjects with generalized anxiety, without producing sedation, tolerance, or withdrawal effects observed with classical anxiolytics.
Research Area 2: Cognitive Enhancement
Selank demonstrates cognitive-enhancing effects that complement its anxiolytic profile. Kozlovskaya et al. (2003) reported that Selank improved memory consolidation and retrieval in rats tested in passive avoidance and active avoidance paradigms. The nootropic effects were especially pronounced under conditions of stress-induced cognitive impairment.
The cognitive effects are attributed to modulation of neurotrophic factors and stabilization of enkephalinergic neurotransmission, which influences hippocampal plasticity and memory encoding processes.
Research Area 3: Immune Modulation
Selank retains and extends the immunomodulatory properties of its parent molecule tuftsin. Uchakina et al. (2008) demonstrated that Selank enhanced IL-6 expression in human monocytes and modulated the balance between pro-inflammatory and anti-inflammatory cytokines. Unlike simple immunostimulants, Selank appears to normalize immune function toward homeostasis.
Yasenyavskaya et al. (2015) showed that Selank influenced the expression of genes involved in immune regulation, with effects on cytokine networks that modulate both innate and adaptive immune responses. This immunomodulatory profile has drawn interest in psychoneuroimmunology research.
Research Area 4: Gene Expression and Genomic Effects
Kolomin et al. (2013) conducted genome-wide expression analysis following Selank administration in rat hippocampus and identified significant changes in 36 genes across multiple functional categories, including neurotransmission, signal transduction, protein modification, and immune response. This genomic fingerprint provides molecular evidence for Selank's multi-target mechanism of action.
Notably, gene expression changes were observed in both neuronal and immune-related pathways simultaneously, confirming the peptide's dual neurotropic-immunomodulatory activity at the transcriptomic level.
Research Area 5: Stress Adaptation
Kozlovskii and Danchev (2003) investigated Selank's effects on the hypothalamic-pituitary-adrenal (HPA) axis stress response. The research demonstrated that Selank modulated the corticosterone response to stress without suppressing it entirely, suggesting an adaptogenic rather than suppressive effect on stress physiology.
This stress-modulating profile, combined with preserved cognitive function under stress conditions, has positioned Selank as a unique research compound in the study of stress resilience mechanisms.
Current Research Status
Selank's clinical use history in Russia provides a substantial safety and efficacy database, while its unique mechanism of action — combining anxiolytic, nootropic, and immunomodulatory effects without sedation or dependence — distinguishes it from conventional anxiolytics. International research continues to explore its molecular mechanisms and potential applications in stress-related and neuroimmune contexts.
Research Disclaimer
This article is for educational and informational purposes only. BeaCapra supplies research peptides for laboratory and research use. Nothing in this article constitutes medical advice.